On January 5, 2010, Silence Therapeutics completed its merger with Intradigm. A new website for the merged company is under development. In the meantime, please visit www.silence-therapeutics.com.

About Us

Business Strategy

Intradigm is executing a dual-pronged strategy to best leverage its drug development expertise and broad RNAi therapeutic platform toward the creation of corporate and shareholder value.

This strategy is based on:

  1. Establishment of multiple partnerships with pharmaceutical and biotechnology companies focused on RNAi therapeutics in a variety of diseases areas
  2. Creation of a high-value internal pipeline of RNAi therapeutics for the treatment of serious diseases